Health Business

SPARC net loss rises to Rs.66 crore in Q3

SPARC-loss-rises

Sun Pharma Advanced Research Company (SPARC) has posted poor performance during the third quarter ended December 2016 and it incurred a higher net loss of Rs.66.33 crore as against Rs.41.02 crore in the corresponding period of last year. Its net sales also declined sharply to Rs.23.06 crore from Rs.33.55 crore. EPS worked out to negative Rs.2.69 as against negative Rs.1.73 in the last period.SPARC-loss-rises

For the nine months ended December 2016, SPARC’s net sales improved by 16.1 per cent to Rs.139.42 crore from Rs.120.11 crore in the similar period of last year. However, its net loss increased to Rs.88 crore from Rs.60.41 crore.

The company raised Rs.250 crore through rights issue and spends Rs.134.15 crore for R&D and general corporate purposes up to the end of December 2016.

With higher losses, SPARC scrip opened at Rs.322 today as against its previous day’s close of Rs.321.90 and then declined to Rs.310.30 in the afternoon session on BSE.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top